In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results. A similar approach could be used for non-communicable diseases where treatment advances have been limited.
- Patrick F. Chinnery
- Marion Bonnet
- Tao You